Chronic Hepatitis C VirusNCT02945228
Drug Use-Results Survey in Participants Infected With Hepatitis C Virus Genotype 2
An observational study of Chronic Hepatitis C Virus, run by AbbVie at 170 sites in Japan.
Trial summary
The main objective of this study is to evaluate the safety and effectiveness of paritaprevir/ritonavir/ombitasvir with ribavirin used for participants infected with chronic hepatitis C virus (HCV) genotype 2 in daily practice in Japan. Read more about this study
- Who is it for?
- Ages 18 to 99 years
- Conditions the study is for
- Chronic Hepatitis C Virus
- How many people
- 449 participants
- Where
- 170 sitesJapan
- Study dates
- 26 Oct 2016to 26 Jul 2019
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 99 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Participants with Chronic hepatitis C virus (HCV) genotype 2
Who may be able to join
- HCV genotype 2 participants treated with paritaprevir/ritonavir/ombitasvir plus ribavirin in daily practice.
Who cannot join
- Participants who have been previously treated with paritaprevir/ritonavir/ombitasvir and ribavirin.
Trial locations and contacts
170 sites in 1 country.
170 sites in 1 country
Japan170 sites
Kato Michio Hepatology Clinic /ID# 159476
Amagasaki, Hyogo, 661-0012
Aomori Prefectural Central Hos /ID# 160822
Aomori, 030-8553
Mantani Clinic /ID# 168353
Arida, 649-0316
Japanese Red Cross Asahikawa /ID# 165265
Asahikawa, 070-0061
Asahikawa City Hospital /ID# 167703
Asahikawa-shi, 070-8610
National Hospital Organization /ID# 168346
Chiba, 260-0042
Chiba University Hospital /ID# 160875
Chiba, 260-8677
Seirei Sakura Citizen Hospital /ID# 166896
Chiba
Kenseido-iin /ID# 164166
Chichibu, 368-0042
University of Yamanashi Hospital /ID# 161770
Chuo-shi, Yamanashi, 409-3898
Fuji City General Hospital /ID# 165278
Fuji
Kusunoki Hospital /ID# 158119
Fujioka, Gunma, 3750024
Fukui Prefectural Hospital /ID# 168344
Fukui, 910-0846
Fukui Prefectural Hospital /ID# 169552
Fukui, 910-0846
University of Fukui Hospital /ID# 166933
Fukui, 910-1104
NHO Kyushu Medical Center /ID# 162956
Fukuoka, Fukuoka, 810-8563
Chihaya Hospital /ID# 161893
Fukuoka
Morichika Internal Medicine /ID# 168351
Fukuyama, 721-0975
NHO Fukuyama Medical Center /ID# 162909
Fukuyama-shi, Hiroshima, 720-8520
Fukuyama City Hospital /ID# 161889
Fukuyama-shi, Hiroshima, 721-8511
Gifu Municipal Hospital /ID# 165287
Gifu, 500-8323
Shiroyama Hospital /ID# 164963
Habikino-osaka, 583-0872
Aomori Rosai Hospital /ID# 167702
Hachinohe
Hamamatsu University Hospital /ID# 171048
Hamamatsu, Shizuoka, 431-3125
Tamakoshi Clinic /ID# 165282
Hamamatsu, 335-0023
Higashihiroshima Medical Ctr /ID# 168343
Higashihiroshima, 739-0041
Mito Medical Center /ID# 171046
Higashiibaraki-gun, 311-3117
Higashiomicity Notogawa Hosp /ID# 161891
Higashiomi, Shiga, 521-1223
Shin-ishikiri Clinic /ID# 169643
Higashiosaka, 579-8013
Wakakusa Daiichi Hospital /ID# 166882
Higashiosaka, 579-8056
Hiroshima Red Cross Hosp Atomi /ID# 162912
Hiroshima, 730-0052
Hiroshima University Hospital /ID# 160815
Hiroshima, 734-8551
Hiroshima-Nishi Medical Center /ID# 169642
Hiroshima, 739-0651
Koyo New Town Hospital /ID# 161890
Hiroshima, 739-1742
Taishi Hospital /ID# 165291
Hyōgo, 671-1561
Iizuka Hospital /ID# 161886
Iizuka, 820-0018
Ikeda Municipal Hospital /ID# 160814
Ikeda, 563-8510
Tokyo Med Uni Ibaraki Med Ctr /ID# 162955
Inashiki, 300-0332
Nippon Med Chiba Hokusoh Hosp /ID# 162902
Inzai, 270-1613
Saitama Medical University Hos /ID# 161768
Iruma-gun, 350-0451
Itoigawa Sogo Hospital /ID# 166884
Itoigawa, 941-0006
Kamiiwade Internal Med-Neuro /ID# 166881
Iwade, 649-6216
Nanpuh Hospital /ID# 168348
Kagoshima, Kagoshima-ken, 8928512
Kaizuka City Hospital /ID# 165256
Kaizuka
Kamisu Saiseikai Hospital /ID# 167701
Kamisu, 314-0112
Fuji Clinic /ID# 160820
Kan’onjichō, 3440067
Kiyokawa Hospital /ID# 164961
Kanagawa, 166-0004
Hiratsuka City Hospital /ID# 161884
Kanagawa
Niwa Hospital /ID# 167684
Kanagawa
Ibaraki Prefectural Cent. Hosp /ID# 164962
Kasama, 309-1703
The Jikei Univ. Kashiwa Hosp. /ID# 166888
Kashiwa-shi, 277-0004
Kashiwazaki General Hospital a /ID# 168352
Kashiwazaki, 945-0035
Kawase Clinic /ID# 164957
Kasugai, 486-0914
Hirose Clinic /ID# 167699
Kawagoe, 350-0043
Sekishindo Hospital /ID# 162960
Kawagoe, 350-1123
Saitama Medical Center, Saitama Medical University /ID# 162911
Kawagoe-shi, Saitama, 350-8550
Kawaguchi Municipal Medical Ce /ID# 165270
Kawaguchi, 333-0833
St. Marianna University School of Medicine Hospital /ID# 160876
Kawasaki, Kanagawa, 216-0015
Kawasaki Municipal Tama Hospit /ID# 165267
Kawasaki, 214-0021
Kanto Rosai Hospital /ID# 165258
Kawasaki-shi, Kanagawa
Kishiwada Tokushukai Hospital /ID# 164964
Kishiwada, Osaka, 596-0042
Kokura Kinen Hospital /ID# 164969
Kitakyushu, 802-0001
Kitasato University Medical Ce /ID# 158120
Kitamoto, 364-0026
Kobe Asahi Hospital /ID# 161896
Kobe, 653-0801
Kobe Adventist Hospital /ID# 161897
Kobe
Tokyo Jikei Daisan Hospital /ID# 164159
Komae-shi, Tokyo, 201-8601
Konan Kosei Hospital /ID# 165277
Konan-shi, 483-8704
Cosmos Clinic /ID# 164161
Kōriyama, 963-0209
Ishida Medical Clinic /ID# 166887
Kōriyama, 963-8023
Dokkyo Medical University Saitama Medical Center /ID# 162907
Koshigaya, Saitama, 343-0813
Hanada Internal Medicine Clin /ID# 165266
Koshigaya, Saitam, 343-0015
Kumamoto University Hospital /ID# 167048
Kumamoto, Kumamoto, 860-8556
Kumamoto Shinto General Hospital /ID# 165275
Kumamoto, Kumamoto, 8628655
Kawasaki Medical School Hosp /ID# 162906
Kurashiki, 701-0114
National Hosp Org Kure Med Cen /ID# 167689
Kure, Hiroshima, 737-0023
Kurihara Central Hospital /ID# 171047
Kurihara, 228-0014
Kuroishi Hospital /ID# 164971
Kuroishi-aomori, 036-0541
Shin Koga Clinic /ID# 164972
Kurume, 830-0033
Koga Hospital 21 /ID# 167698
Kurume, 839-0801
Kurume University Hospital /ID# 164158
Kurume-shi, Fukuoka, 830-0011
Hori Internal Medicine Clinic /ID# 167696
Kushiro, 085-0005
NHO Kyoto Medical Center /ID# 162910
Kyoto, 612-0861
Matsuzaki Internal Medicine Cl /ID# 164970
Kyoto, 615-8101
Gibo Hepatorogy Clinic /ID# 161766
Matsumoto, 399-0036
Matsuyama Red Cross Hosp /ID# 162953
Matsuyama, Ehime, 7900826
Kizawa Memorial Hospital /ID# 162957
Minokamo, 505-0034
Sumiyoshi Clinic Hospital /ID# 164163
Mito, 310-0844
South Miyagi Medical Center /ID# 164965
Miyagi, 989-1253
National Hospital Organization /ID# 168345
Miyakonojō, 885-0014
Miyazaki Medical Center Hospit /ID# 165279
Miyazaki, 880-0003
University of Miyazaki Hosp /ID# 166880
Miyazaki, 889-1692
Matsushita Memorial Hospital /ID# 167693
Moriguchi-shi, 570-0096
Aichi Medical University Hosp /ID# 161892
Nagakute, Aichi-ken, 4801195
Suzuki Clinic /ID# 165264
Nagareyama, 270-0157
Meitetsu Hospital /ID# 165288
Nagoya, 451-8511
Nagoya Central Hospital /ID# 166879
Nagoya, 453-0801
Aikawa Minnano-shinryojo /ID# 164168
Nagoya, 458-0011
Meijo Hospital /ID# 164966
Nagoya-aichi, 460-0001
Nara City Hospital /ID# 162959
Nara, 530-0025
Tani Internal Medicine Clinic /ID# 164974
Nayoro, 096-0018
Ooka Clinic /ID# 161887
Nishinomiya, 663-8124
The Hospital of Hyogo College of Medicine /ID# 162913
Nishinomiya-shi, Hyōgo, 663-8501
Noshiro Yamamoto Med. Assoc. /ID# 162964
Noshiro, 016-0151
Manna Clinic /ID# 169548
Odawara, 250-0214
Oita Midical Center /ID# 164960
Ōita, 870-0263
Okayama University Hospital /ID# 165268
Okayama, Okayama-ken, 700-8558
Okayama Saiseikai Outpatient Center Hospital /ID# 159475
Okayama, 700-0013
Omuta City Hospital /ID# 164967
Omuta, 836-0861
Kita-harima Medical Center /ID# 164165
Ono, 675-1327
Onomichi Central General Hospi /ID# 162903
Onomichi
Osaka Red Cross Hospital /ID# 161888
Osaka, Osaka, 543-8555
Osaka City University Hospital /ID# 165290
Osaka, Osaka, 545-0051
Nippon Life Saiseikai Public Interest Foundation Nippon Life Hospital /ID# 167688
Osaka, Osaka, 550-0006
Kenporen Osaka Central Hospita /ID# 164956
Osaka, 530-0001
Asai Naika /ID# 167691
Osaka, 537-0024
Osaka Inter. Cancer Institute /ID# 166889
Osaka, 541-8567
Osaka Police Hospital /ID# 161769
Osaka, 543-0035
Asai Naika Iin /ID# 164955
Osaka, 546-0043
Utajima Ueda Clinic /ID# 161894
Osaka, 555-0012
Tamai Clinic /ID# 164162
Osaka, 557-0002
Osaka Hospital /ID# 164157
Osaka, 572-0854
Seko Internal Medicine Clinic /ID# 164169
Ōtsu, 520-0802
Kawazoe Internal Medicine Clin /ID# 165292
Saga, 849-1113
Saitama Citizens Medical Ctr /ID# 169550
Saitama, 331-0054
Sainokuni Higashiomiya Medical /ID# 167700
Saitama, 331-0804
Honda Internal Clinic /ID# 161767
Saitama, 349-0115
Saitama Cooperative Hospital /ID# 167697
Saitama
Minamitani Clinic /ID# 160821
Sakai, 590-0026
Kaisei Hospital /ID# 164973
Sapporo, 001-0033
Sendai Kousei Hospital /ID# 162961
Sendai, 980-0873
Tokyo Women's Medical University Hospital /ID# 167685
Shinjuku-ku, Tokyo, 162-8666
Saka General Hospital /ID# 162962
Shiogama-miyagi, 985-0024
Saiseikai Suita Hospital /ID# 165289
Suita, 564-0013
Suita Municipal Hospital /ID# 164958
Suita-osaka, 564-0082
Kagawa Prefectural Central Hos /ID# 160816
Takamatsu, 760-0065
Sawada Hepatology & Gastro /ID# 165255
Takaraduka, 665-0881
National Hospital Organization Takasaki General Medical Center /ID# 160877
Takasaki-shi, Gunma, 370-0829
Tenjin Tanaka Internal Medicin /ID# 166883
Takatsuki, 569-1123
Osaka Medical College Hospital /ID# 162908
Takatsuki -shi, Osaka, 569-8686
Hamada Clinic /ID# 171045
Tatebayashi, 374-0053
Todachuo General Hospital /ID# 165280
Toda-shi, Saitama, 335-0023
Eastern Chiba Medical Center /ID# 165257
Togane, Chiba, 283-0826
Delta Clinic /ID# 164167
Tokorozawa, 359-0037
The Jikei University Hospital /ID# 169547
Tokyo, 105-8461
Abbott Japan /ID# 144983
Tokyo, 108-6303
Juntendo University Hospital /ID# 161771
Tokyo, 113-8431
Nippon Medical School Hospital /ID# 164164
Tokyo, 113-8602
Tokyo Metropolitan Bokutoh Hos /ID# 167686
Tokyo, 130-8575
Ohashi Medical Office /ID# 164968
Tokyo, 173-0021
Juntendo Univ Nerima Hosp /ID# 164160
Tokyo, 177-0033
JP Red Cross Musashino Hosp /ID# 162904
Tokyo, 180-8610
Ehime University Hospital /ID# 161885
Tōon, 791-0204
Toyama University Hospital /ID# 169551
Toyoma, 930-0194
Toyonaka Municipal Hospital /ID# 167692
Toyonaka, 560-8565
Mie Syokaki Clinic /ID# 161895
TSU, MIE, 514-0062
Saiseikai Utsunomiya Hospital /ID# 162958
Utsunomiya, 321-0974
Seike Clinic /ID# 166890
Uwajima, 798-0032
Saiseikai Wakayama Hospital /ID# 162954
Wakayama, 640-8158
Wakayama Rosai Hospital /ID# 165254
Wakayama, 640-8505
Tokyo Women's Medical Universi /ID# 167694
Yachiyo, 276-0046
Tohoku Central Hospital /ID# 166897
Yamagata, 990-0064
Okuda Gastrointestinal Medicin /ID# 168349
Yamaguchi, 753-0047
Kainan Hospital /ID# 164959
Yatomi-shi, 498-0017
Kumamoto Rosai Hospital /ID# 167695
Yatsushiro-shi
Mie Prefectural General Medica /ID# 162963
Yokkaichi, 510-0885
Yokohama City Univ Medical Ctr /ID# 162905
Yokohama, Kanagawa, 232-0024
Showa Univ Fujigaoka Hosp /ID# 162952
Yokohama, 227-0043
Oita University Hospital /ID# 169549
Yufu-shi, 879-5503
Yamaguchi Surgery Clinic /ID# 167704
Yugawara, 259-0313
Josai Hospital /ID# 168347
Yūki, 307-0001
About this study
Official title: Drug Use-Results Survey in Patients Infected With Hepatitis C Virus Genotype 2
The main objective of this study is to evaluate the safety and effectiveness of paritaprevir/ritonavir/ombitasvir with ribavirin used for participants infected with chronic hepatitis C virus (HCV) genotype 2 in daily practice in Japan.
- Conditions
- Chronic Hepatitis C Virus
- Keywords
- Genotype 2, Paritaprevir, Hepatitis C Virus (HCV), Ritonavir, Ombitasvir
- Medical subject headings
- Hepatitis C, Chronic, Hepatitis C
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Chronic infection of hepatitis C virus (HCV) genotype 2 | Participants with confirmed chronic HCV genotype 2, receiving paritaprevir/ritonavir/ombitasvir and ribavirin according to standard of care and in line with the current local label |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants with Sustained Virologic Response (SVR12)
Hepatitis C virus (HCV) ribonucleic acid (RNA) less than the lower limit of quantification (LLOQ) 12 weeks after the last dose of study drug.
Measured: 12 weeks after last dose of study drug.
Secondary outcomes (3)
Percentage of Participants with Virologic Failure During Treatment (breakthrough)
HCV RNA levels reach less than the LLOQ, then increase to greater than or equal to the LLOQ at any point during treatment.
Measured: Up to 12 Weeks
Percentage of Participants with Virologic Failure After Treatment (relapse)
Undetectable viremia (HCV RNA less than LLOQ) at the end of the 16 weeks treatment but subsequent viremia (HCV RNA greater than or equal to LLOQ) during the follow-up period of 24 weeks after treatment.
Measured: Post-treatment 24 weeks
Percentage of Participants with Sustained Virologic Response (SVR24)
HCV RNA less than the LLOQ 24 weeks after the last dose of study drug.
Measured: 24 weeks after the last dose of study drug
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Oct 2016 (estimated)
- Study start26 Oct 2016
- Primary completion26 Jul 2019
- Study completion26 Jul 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Hepatitis C VirusStudies of the same condition, open and under way.
- More trials run by AbbVieThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 449 participants (actual)
Sponsor and investigators
- Lead sponsor
- AbbVie
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- AbbVie Inc., Study director, AbbVie
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02945228
- Sponsor's protocol ID
- P15-764
- Status last verified
- Jun 2020
- First submitted
- 25 Oct 2016
- Last updated
- 12 Jun 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 12 Jun 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Drug Use-Results Survey in Patients Infected With Hepatitis C Virus Genotype 2
- ClinicalTrials.gov ID
- NCT02945228
- Acronym / sponsor ID
- P15-764
- Conditions
- Chronic Hepatitis C Virus
- Keywords
- Genotype 2, Paritaprevir, Hepatitis C Virus (HCV), Ritonavir, Ombitasvir
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 449 participants (actual)
- Lead sponsor
- AbbVieIndustry (pharma, biotech, devices)
- Study start
- 26 Oct 2016 (actual)
- Primary completion
- 26 Jul 2019 (actual)
- Study completion
- 26 Jul 2019 (actual)
- First posted
- 26 Oct 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main objective of this study is to evaluate the safety and effectiveness of paritaprevir/ritonavir/ombitasvir with ribavirin used for participants infected with chronic hepatitis C virus (HCV) genotype 2 in daily practice in Japan.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Chronic infection of hepatitis C virus (HCV) genotype 2 | – | –Participants with confirmed chronic HCV genotype 2, receiving paritaprevir/ritonavir/ombitasvir and ribavirin according to standard of care and in line with the current local label |
Who may qualify
- Ages
- 18 to 99 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Participants with Chronic hepatitis C virus (HCV) genotype 2
Key inclusion criteria (1 listed)
- HCV genotype 2 participants treated with paritaprevir/ritonavir/ombitasvir plus ribavirin in daily practice.
Key exclusion criteria (1 listed)
- Participants who have been previously treated with paritaprevir/ritonavir/ombitasvir and ribavirin.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Percentage of Participants with Sustained Virologic Response (SVR12)
Time frame: 12 weeks after last dose of study drug.
Hepatitis C virus (HCV) ribonucleic acid (RNA) less than the lower limit of quantification (LLOQ) 12 weeks after the last dose of study drug.
3 secondary outcomes
Percentage of Participants with Virologic Failure During Treatment (breakthrough)
Time frame: Up to 12 Weeks
Percentage of Participants with Virologic Failure After Treatment (relapse)
Time frame: Post-treatment 24 weeks
Percentage of Participants with Sustained Virologic Response (SVR24)
Time frame: 24 weeks after the last dose of study drug
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Jun 2020.
- Individual participant dataSharing planned: Undecided
Related trials for Chronic Hepatitis C Virus
RecruitingObservational study
Evaluation of Patients With Liver Disease
Hepatitis D, Hepatitis C
Active, not recruitingPhase 4
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
Diabetes Mellitus, Hepatitis C, Chronic
RecruitingObservational study
"Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases".
Chronic Liver Disease and Cirrhosis, Liver Cancer
Active, not recruitingPhase 4
Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy
Hepatitis C, Chronic, Pregnancy; Infection
Enrolling by invitationObservational study
Comparative Autoantibody and Immunologic Cell Marker Study
Autoimmune Diseases, Lupus Erythematosus, Systemic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
AbbVie Inc. study director
AbbVie
170 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Chronic Hepatitis C Virus, run by AbbVie at 170 sites in Japan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Jun 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 170 sites in Japan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants with Sustained Virologic Response (SVR12) (time frame: 12 weeks after last dose of study drug.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jun 2020.